
MSD joins Medivation race, says reports
pharmafile | August 18, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing |Â Â MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeoverÂ
MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology drugs firm Medivation, according to a report by Reuters.
Medivation has been the target of a very public sustained pursuit from Sanofi in recent months. They rejected an initial $9.3 billion bid, but Sanofi has taken numerous measures to try push a sale, including proposing the replacement of the board at the company to one more amenable to Sanofi’s bid.
The company has one bona fide blockbuster in the form of Xtandi (enzalumatide), as well as a promising pipeline of cancer medicines.
Other players mulling a bid include Pfizer, Celgene and Gilead. For MSD, Medivation would provide an effective complement to its existing cancer portfolio, which includes immune-oncology treatment Keytruda (pembrolizumab). Their position was recently strengthened by Opdivo’s failure in a Phase III trial.
Medivation shares have been on a steady rise following Sanofi’s very public overtures, rising again as high as $66.59 upon the news of MSD’s interest. At the beginning of February, the share price was as low as $27.32.
Sean Murray
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …






